 | Up a level |
Mueller, F; Büchel, B; Köberle, D; Schürch, Stefan; Pfister, B; Krähenbühl, St; Fröhlich, Tanja; Largiader, C R; Joerger, M (2013). Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer chemotherapy and pharmacology, 71(2), pp. 361-70. Berlin: Springer 10.1007/s00280-012-2018-4
Tarantino, I; Warschkow, R; Worni, M; Merati-Kashani, K; Köberle, D; Schmied, B M; Müller, S A; Steffen, T; Cerny, T; Güller, U (2012). Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. British journal of cancer, 107(2), pp. 266-74. Basingstoke: Nature Publishing Group 10.1038/bjc.2012.267
Ruhstaller, T; Widmer, L; Schuller, J C; Roth, A; Hess, V; Mingrone, W; von Moos, R; Borner, M; Pestalozzi, B C; Balmermajno, S; Köberle, D; Terraciano, L; Schnider, A; Bodis, S; Popescu, R (2009). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology, 20(9), pp. 1522-8. Oxford: Oxford University Press 10.1093/annonc/mdp045
Roth, AD; Fazio, N; Stupp, R; Falk, S; Bernhard, J; Saletti, P; Köberle, D; Borner, MM; Rufibach, K; Maibach, R; Wernli, M; Leslie, M; Glynne-Jones, R; Widmer, L; Seymour, M; de Braud, F; Swiss, Group for Clinical Cancer Research (2007). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology, 25(22), pp. 3217-23. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2006.08.0135
